Studying Interferon Gamma to Prevent Secondary Infections in Adults with ICU-acquired Immune Suppression
Led by University Hospital, Limoges · Updated on 2025-11-20
326
Participants Needed
23
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of Interferon gamma to prevent secondary infections in patients with sustained immunosuppression acquired in the ICU. This phase 3 randomized trial aims to assess whether Interferon gamma reduces the number of secondary infection episodes at three months, lowers ICU mortality at day 90, shortens ICU and hospital stays, and promotes biological immune restoration by day 10. The study also examines cost-effectiveness and safety of Interferon gamma compared to a placebo.
Participants will receive injections of Interferon gamma-1b or a placebo subcutaneously, preferably in the deltoid area or the front thigh. They will be given up to five injections between day 1 and day 9. The placebo consists of a saline solution with the same volume as the active drug. The treatment period lasts for up to nine days.
During the trial, participants will be monitored daily until they leave the ICU, with follow-up visits at days 30, 60, and 90. Researchers will assess infection rates, causes of death, length of ICU and hospital stay, antibiotic and antifungal use, immune system recovery, healthcare costs, and any serious adverse reactions. The total participation duration extends to 90 days after treatment begins to evaluate outcomes and safety.
CONDITIONS
Brief Title
Prevention of Secondary Infections by Interferon Gamma in ICU-acquired Sustained Immune-suppression
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Adult patient hospitalized in the ICU for at least 1 week
Expected length of stay in the ICU greater than 10 days at screening
At least 1 episode of multiple organ failure, defined as a SOFA 26 6 (excluding the respiratory component when related to a neurological failure), during the first 1 week of ICU hospitalization
Immunosuppression defined as an mHLA-DR < 8000 Ab/c and a lymphopenia < 1000/mm3 within a 96 hours time window
Patient or the legal representative giving consent must be able to understand the trial in its entirety
Patient affiliated to the social security system
For female participants of childbearing potential, agreement to use dual methods of contraception until Day 90
For male participants with female partners of childbearing potential, agreement to use barrier method of contraception until Day 90.
You will not qualify if you...
Uncontrolled secondary infections ongoing at the time of screening
Participation in another research clinical trial within 30 days
Chemotherapy or radiation therapy within the last 6 weeks
Apache II 26 30 at screening
History of autoimmune disease
Organ or bone marrow transplant
History of hematologic malignancy
History of hepatitis C
HIV stage C within the last 12 months
Patients under legal protection
History of or ongoing tuberculosis
Chronic hepatitis B
Patients receiving immunosuppressive medications including steroid doses greater than 1mg/kg/day of prednisone equivalent for more than 1 week and corticosteroid use for more than 3 months
Patient with thrombocytopenia below 50,000/mm3
Patient with traumatic brain and spinal injury
Pregnancy or breast feeding
Subjects with hypersensitivity to interferon gamma or its excipients, known latex hypersensitivity or other interferon
Hepatic cytolysis with AST/ALT > 5 times ULN
Suspected acute pancreatitis with lipase or amylase > 3 times ULN
Severe chronic renal failure with eGFR <10 ml/min/1.73m2
Acute life-threatening ECG abnormalities such as myocardial infarction, ventricular fibrillation or tachycardia
Mental state impairing consent understanding
Patient deprived of liberty by judicial or administrative decision
Investigator or related staff involved in the trial or their relatives directly involved in the trial, including assistant doctors, pharmacists, nurses, trial coordinators.
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - 9 days
Participants receive subcutaneous injections of interferon gamma-1b or placebo, with 5 injections between day 1 and day 9.
Up to 5 injection visits
Follow-up
Duration - Up to 90 days
Participants are monitored for secondary infections, immune restoration, adverse reactions, and other health outcomes up to day 90 after treatment.
Periodic visits up to Day 90
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Prevention of secondary infections by interferon-gamma in ICU-acquired sustained immune suppression in France: study protocol of the PLATINIUM randomised trial.
Ana C Hernandez Padilla, Thomas Daix, Richard S Hotchkiss...